VRC-HIVMAB060-00-AB

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV AntibodiesHIV InfectionHIV-1 InfectionMonoclonal AntibodyMonoclonal Antibody, HumanNeutralizing AntibodyVRC01 Monoclonal AntibodyViral Load

Phase 1

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

CompletedNCT01950325

National Institute of Allergy and Infectious Diseases (NIAID)HIV-1 Infection, HIV Antibodies, Monoclonal Antibody +2

Start: 2013-08-22End: 2015-08-20Updated: 2019-12-17

Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults

CompletedNCT01993706

National Institute of Allergy and Infectious Diseases (NIAID)HIV Antibodies, HIV Infection, Monoclonal Antibody, Human +2

Start: 2013-11-19End: 2015-02-27Updated: 2019-12-17